All of the focus seems to be on Allergan (AGN) - Get Report after rumors of potential merger discussions with Pfizer (PFE) - Get Report , which has pushed Allergan shares up nearly 9% on Thursday. Pfizer is flat.
But while Allergan is part of Jim Cramer's Action Alerts PLUS portfolio, he said on on CNBC's "Stop Trading" segment he is more impressed by a much smaller stock: Revance Therapeutics (RVNC) - Get Report .
The reason is Botox.
Allergan has a market cap north of $110 billion while Revance's is just $640 million. However, Revance's latest phase 2 results for its wrinkle-fighting treatment topped both placebo and treatments with Botox, Allergan's marquee product.
This has sent Revance shares up 26% Thursday and 102% for the year, Cramer pointed out.
Cramer said there is much more competition now, not just in the Botox world, but in many different facets of biotech and health care -- something investors should keep an eye on.
At the time of publication, Cramer's Action Alerts PLUS had a long position in AGN.